secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001104659-25-110829
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma reports Q3 net loss $4.0M; Phase 2 ratutrelvir data expected YE 2025
--------------------------------------------------------------------------------

- Net loss of $4.0M ($0.34 diluted EPS) vs $8.5M ($1.49) in Q3 2024; R&D and G&A expenses down significantly.
- Cash and equivalents $6.4M at Sept 30, 2025, down from $21.3M at Dec 31, 2024; runway into Q1 2026.
- Acquired key patent from Viriom for $2.6M; intangible assets of $2.6M recorded.
- Ratutrelvir Phase 2 studies dosed; topline data from both studies expected by year-end 2025.
- Iain Dukes permanently appointed CEO, Charles Parker CFO confirmed Oct 6; John Leaman added to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925110829/0001104659-25-110829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925110829/tm2531045d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-110829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer